BRITISH MEDICAL BULLETIN

VOLUME THIRTY-THREE
1977

MULTIPLE SCLEROSIS

Scientific Editor · · · · · · · · J S PORTERFIELD

*

SOMATIC AND VISCERAL
SENSORY MECHANISMS

Scientific Editor · · · · · · · · · G GORDON

*

HAEMOSTASIS

Scientific Editor · · · · · · · · DUNCAN THOMAS

*

Managing Editor · O M HARRISON

MEDICAL DEPARTMENT · THE BRITISH COUNCIL · 65 DAVIES STREET · LONDON · W1Y 2AA

CONTENTS OF VOLUME THIRTY-THREE

NUMBER 1. *Multiple Sclerosis*

Scientific Editor: J S PORTERFIELD

		PAGE
Introduction	*J H D Millar*	1
Diagnosis and classification of multiple sclerosis	*W I McDonald & A M Halliday*	4
Epidemiology of multiple sclerosis	*E D Acheson*	9
Pathology of multiple sclerosis: progression of the lesion	*C W M Adams*	15
Pathophysiology of demyelinating disease	*A M Halliday & W I McDonald*	21
Laboratory diagnosis of multiple sclerosis: immunological and biochemical aspects	*E J Thompson*	28
Multiple sclerosis: a virus disease?	*K B Fraser*	34
Significance of virus antibodies in multiple sclerosis	*Margaret Haire*	40
Cellular immunity in multiple sclerosis	*Stella C Knight*	45
Humoral factors involved in immune processes in multiple sclerosis and allergic encephalomyelitis	*E A Caspary*	50
Immunopathology of demyelination in autoimmune diseases and virus infections	*Henryk M Wiśniewski*	54
Immunochemistry and biochemistry of myelin	*A N Davison & M Louise Cuzner*	60
Relevance of fatty acids in multiple sclerosis	*J Mertin & C J Meade*	67
Histocompatibility antigens and their relevance to multiple sclerosis	*J R Batchelor*	72
Treatment and management of multiple sclerosis	*L A Liversedge*	78

Notes on Contributors 84

Book Reviews 86

NUMBER 2. *Somatic and Visceral Sensory Mechanisms*

Scientific Editor: G GORDON

		PAGE
Introduction	*G S Brindley*	89
Henry Head: his influence on the development of ideas on sensation	*R A Henson*	91
Cutaneous and subcutaneous sense organs	*A Iggo*	97
Cutaneous hyperalgesia	*Bruce Lynn*	103
Cutaneous axons and sensory neurones in the spinal cord	*A G Brown*	109
Somaesthetic pathways	*K E Webster*	113
Subcortical mechanisms concerned in somatic sensation	*A G Brown & G Gordon*	121
The somatic sensory cortex	*T P S Powell*	129
Muscle afferents and kinaesthesia	*Peter B C Matthews*	137
Temperature sense in the primate	*Ian Darian-Smith & Kenneth O Johnson*	143
Pain	*P W Nathan*	149
Opioid peptides	*J Hughes & H W Kosterlitz*	157
Abdominal and pelvic visceral receptors	*B F Leek*	163
Thoracic receptors connected with sensation	*A S Paintal*	169
Respiratory sensations in man	*A Guz*	175

Notes on Contributors 178

Book Reviews 180

NUMBER 3. *Haemostasis*

Scientific Editor: DUNCAN THOMAS

		PAGE
Introduction	*R G Macfarlane*	183
Normal and abnormal haemostasis	*J F Mustard & M A Packham*	187
Fluid-mechanical and biochemical interactions in haemostasis	*G V R Born*	193
Biochemical aspects of platelet behaviour associated with surface membrane reactivity	*N Crawford & D G Taylor*	199
Disorders of platelet function	*R M Hardisty*	207
Biochemistry of blood coagulation	*M P Esnouf*	213
Factor VIII and its inherited disorders	*A L Bloom & I R Peake*	219
Clinical management of haemophilia	*C R Rizza*	225
Physiological mechanisms in coagulation and fibrinolysis	*Milica Brozović*	231
Normal and abnormal fibrinolysis	*P B A Kernoff & G P McNicol*	239
Structure of fibrinogen and degradation products of fibrinogen and fibrin	*Patrick J Gaffney*	245
Disorders of plasma fibrinogen synthesis	*P T Flute*	253
Investigation of a long-standing bleeding tendency	*G I C Ingram*	261
Diagnosis and management of disseminated intravascular coagulation	*A A Sharp*	265
Blood replacement therapy	*S J Urbaniak & J D Cash*	273
Population-based distributions of haemostatic variables	*T W Meade & W R S North*	283

Notes on Contributors 289

Book Reviews 292

INDEX TO VOLUME THIRTY-THREE

Names printed in capitals are those of authors who have contributed papers. Titles of books are printed in italics.

A

Acetylsalicylic acid, contra-indications to use in haemophilia, 229
——effects on bleeding time, 189
————platelets, 211, 229
ACHESON E D: Epidemiology of multiple sclerosis, 9
ADAMS C W M: Pathology of multiple sclerosis: progression of the lesion, 15
Adenosine diphosphate, platelet adhesion activities, 187, 202
Afferent nerves, role in kinaesthesia, 137
Afibrinogenaemia, 190
Agonists, opiate, 157
Analgesia, stimulation-produced, 153
Antibody, abnormal, in multiple sclerosis, 36
Antigens, histocompatibility, in multiple sclerosis, 13
Antihistamines as inflammatory mediators, 104
Antiplasmins, 240
Antithrombin III, 234
Arterial chemoreceptors connected with sensation, 172
Auditory evoked potentials in multiple sclerosis, 5
Autoimmune diseases, demyelination in, immunopathology, 54
—mechanisms in multiple sclerosis, 69
Autoimmunity in multiple sclerosis, 37
Axons, cutaneous, spinal, 109, 111

B

BATCHELOR J R: Histocompatibility antigens and their relevance to multiple sclerosis, 72
Bernard–Soulier syndrome, 189, 207
Biggs R (editor): *Human blood coagulation, haemostasis and thrombosis*, 2nd ed., 292
Biochemistry and neurological disease, 181
Biographical notes on contributors, 84, 178, 289
Bleeding tendency, long-standing, investigation, 261
Blink reflex, 5
Blood clotting factors, defects, 263
—coagulation, acute-phase reaction, 233
——and fibrin formation, 188
——biochemistry, 213
——congenital disorders, 188
——effects of hormones, 235
——factors, 273
————defects, 263
—— *Human blood coagulation, haemostasis and thrombosis*, 2nd ed., 292
——intravascular, disseminated, diagnosis and management, 265
——physiological mechanisms, 231
—in diagnosis of multiple sclerosis, 31
—lipid changes in multiple sclerosis, 64
—platelets, activation, physical versus chemical, 195
——activation time in vitro, 194
————in vivo, 194
——adhesion defects, 189, 207
——aggregation deficiency, 190
——behaviour, biochemical aspects associated with surface membrane reactivity, 199
——defects of release reaction, 208
——disorders, functional, 207
————acquired, 210
————hereditary, 188, 207
——effects of drugs on, 189, 211
——haemostatic reactivity, 196
——in treatment of coagulation deficiencies, 276
——plasma membranes, 200
————mediated processes, initiation and propagation, 202
——storage pool deficiency, 208, 210
——ultrastructure, 199
—replacement therapy, 273
BLOOM A L & PEAKE I R: Factor VIII and its inherited disorders, 219
Book reviews, 86, 180, 292
BORN G V R: Fluid-mechanical and biochemical interactions in haemostasis, 193
Brain, somaesthetic pathways, 117
Brain-stem, bulbar, somaesthetic function, 117
—lesions and multiple sclerosis, 7
BRINDLEY G S: Somatic and visceral sensory mechanisms. Introduction to symposium, 89

INDEX TO VOLUME THIRTY-THREE

BROWN A G: Cutaneous axons and sensory neurones in the spinal cord, 109
—& GORDON G: Subcortical mechanisms concerned in somatic sensation, 121
BROZOVIĆ M: Physiological mechanisms in coagulation and fibrinolysis, 231

C

Cardiovascular receptors connected with sensation, 172
Carp's granulocytopenic agent, 37
CASH J D, *see* URBANIAK S J, 273
CASPARY E A: Humoral factors involved in immune processes in multiple sclerosis and allergic encephalomyelitis, 50
Cerebral cortex, sensory system, 95
——somatic, sensation in, 129
Cerebrospinal fluid immunoglobulins in multiple sclerosis, 31
——in multiple sclerosis, 6, 28
——lipids, 31
——proteins, 28, 30
CHAKRABARTI R, *see* MEADE T W, 283
Coagulation factors in whole blood, 273
Collagen, blood platelet adhesion, defects, 187, 207
Contraceptives, oral, effect on fibrinolysis, 236
Contributors, biographical notes on, 84, 178, 289
Corticotropin, effect on fibrinolysis, 236
Coumarin and clotting factors, 188
CRAWFORD N & TAYLOR D G: Biochemical aspects of platelet behaviour associated with surface membrane reactivity, 199
Cuatrecasas P & Greaves M F (editors): *Receptors and recognition.* Series A: Vol. 1, 180
CUZNER M L, *see* DAVISON A N, 60
Cyclo-oxygenase deficiency of platelets, 209

D

DARIAN-SMITH I & JOHNSON K O: Temperature sense in the primate, 143
DAVISON A N & CUZNER M L: Immunochemistry and biochemistry of myelin, 60
—(editor): *Biochemistry and neurological disease*, 181
—Humphrey J H, Liversedge L A, McDonald W I & Porterfield J S (editors): *Multiple sclerosis research*, 86
Demyelinating disease, pathophysiology, 21
Demyelination, 34
—acute, time-course of recovery, 22
—and delayed impulse conduction, 23
—cell-mediated, antibody-dependent, 58
—effects on nerve conduction, 21
—immunopathology, in autoimmune diseases and virus infections, 54
—virus-induced, 54
Dorsolateral quadrant, somaesthetic pathway, 115
Drugs, effects on platelet function, 211
—stimulation of fibrinolysis, 241
Dysfibrinogenaemia, hereditary, 255

E

Ehlers–Danlos syndrome, 207
Electro-oculography in multiple sclerosis, 5
Electrospinogram in multiple sclerosis, 5
Encephalomyelitis, allergic, extracerebral changes, 64
——immune processes, humoral factors in, 50
Enkephalins, 157
—*Opiates and endogenous opioid peptides*, 180
—pharmacology, 158
—physiological functions, 159
Enzymes, lysosomal, in multiple sclerosis lesion, 16, 62
Epidemiology, distributions of haemostatic variables, 283
Epidemiology of multiple sclerosis, 9
Erythralgia, mechanism of, 103
ESNOUF M P: Biochemistry of blood coagulation, 213
Europeans, epidemiology of multiple sclerosis in, 10
Exercise, effects on patients with multiple sclerosis, 25
—graded, and coagulation factors, 232

F

Factor VIII, 208, 219, 231, 232, 234, 263
——antibodies in haemophiliacs, management, 227
——concentrates in treatment of coagulation disorders, 278
——levels by ABO blood-group status, ethnic group and sex, 286
——molecular variants, 222
——nature, 220
——physiological role, 221
——-related activities, 219
———antigen, 221
——replacement therapy, 228
—IX concentrates in treatment of coagulation deficiencies, 279
—X extrinsic activator, 214
——intrinsic activator, 213
Factors VII–XIII, effects of deficiency, 188
—blood-clotting, defects, 263
Fatty acids, relevance in multiple sclerosis, 67
Fibrin, degradation products, 249, 269
—formation, and blood coagulation, 188
—interactions with plasmin, 249
Fibrinogen, degradation products, 247, 269
———effects on platelet aggregation, 210
—in treatment of coagulation deficiencies, 280
—interactions with plasmin, 248
—plasma concentrations, increased and decreased, 253
———relationship with age, 287
—structure, 245
—synthesis, disorders, 253
Fibrinolysis, abnormal, 242
—activators, 240
—biological roles, 243
—inhibitors, 240
—mechanisms, 241
—normal, 239
—pharmacological enhancement, 241
—physiological mechanisms, 231
—variations in disease, 242
——physiological, 242
Fibrinolytic "shut down", 234
FLUTE P T: Disorders of plasma fibrinogen synthesis, 253
FRASER K B: Multiple sclerosis: a virus disease? 34

G

GAFFNEY P J: Structure of fibrinogen and degradation products of fibrinogen and fibrin, 245
Glucocorticoids, effect on fibrinolysis, 236
Gluten-free diet in multiple sclerosis, 79
GORDON G, *see* BROWN A G, 121
Greaves M F, *see* Cuatrecasas P, 180
GUZ A: Respiratory sensations in man, 175

H

Haemolytic reactions in blood replacement therapy, 281
Haemophilia carrier, detection, 223
—clinical management, 225
—dental care in, 227
—factor-VIII replacement therapy, 228
———variants in, 222
—management, corticosteroids, 229
——fibrinolysis inhibitors, 229
Haemophilia, management, local haemostasis, 229
—pain in, management, 229
—treatment, domiciliary, 227
Haemophiliacs, management during dental treatment, 227
—management during major surgery, 227
—with factor-VIII antibodies, management, 227
Haemorrhage in haemophilia, management, 226
Haemostasis, 183–292
—abnormal, 188
—arteriolar, haemodynamic conditions during, 193
—biochemical interactions in, 193
—disorders, 263
—fluid-mechanical interactions in, 193
—*Haemostasis: biochemistry, physiology, and pathology*, 292
—*Human blood coagulation, haemostasis and thrombosis*, 2nd ed., 292
—introduction to symposium, 183
—modifications, effects, 188
—normal, 187
——mechanism, 187
—variables, population-based distribution, 283
HAINES A P, *see* MEADE T W, 283
Hair follicle afferent collaterals, relations with spinocervical tract neurones, 110
HAIRE M: Significance of virus antibodies in multiple sclerosis, 40
HALLIDAY A M & McDONALD W I: Pathophysiology of demyelinating disease, 21
—*see* McDONALD W I, 4
HARDISTY R M: Disorders of platelet function, 207
Head, Henry, influence on development of ideas on sensation, 91
HENSON R A: Henry Head: his influence on the development of ideas on sensation, 91
Heparin: *Heparin: chemistry and clinical usage*, 292
—therapy of disseminated intravascular coagulation, 270
Hepatitis complicating factor-VIII replacement therapy, 228
—post-transfusion, 281
Hermansky–Pudlak syndrome, 209
Histocompatibility antigens in multiple sclerosis, 13
——relevance to multiple sclerosis, 72
HLA complex, association with multiple sclerosis, 72, 76
Hormones, effect on blood coagulation, 235
HUGHES J & KOSTERLITZ H W: Opioid peptides, 157
Humoral factors in immune processes in multiple sclerosis and allergic encephalomyelitis, 50
Humphrey J H, *see* Davison A N, 86
Hyperalgesia, cutaneous, 103
Hypervolaemia complicating factor-VIII replacement therapy, 228
Hypofibrinogenaemia, 254

I

IGGO A: Cutaneous and subcutaneous sense organs, 97
—& Ilyinsky O B (editors): *Somatosensory and visceral receptor mechanisms*, 180
Ilyinsky O B, *see* Iggo A, 180
Immunity, cell-mediated, in multiple sclerosis, 37
—cellular, in multiple sclerosis, 45
Immunoglobulins, determination in multiple sclerosis, 29
—relations with clinical course of multiple sclerosis, 31
Immunological adjuvants: Report of a WHO Scientific Group, 87

INDEX TO VOLUME THIRTY-THREE

Immunological diagnosis of multiple sclerosis, 28
Inflammation, mediators, 104
INGRAM G I C: Investigation of a long-standing bleeding tendency, 261

J

Japanese, epidemiology of multiple sclerosis in, 11
Jews, epidemiology of multiple sclerosis in, 11
JOHNSON K O, *see* DARIAN-SMITH I, 143

K

Kakkar V V & Thomas D P (editors): *Heparin: chemistry and clinical usage*, 292
KERNOFF P B A & McNICOL G P: Normal and abnormal fibrinolysis, 239
Kinaesthesia, role for muscle afferents, 137
Kinins as inflammatory mediators, 105
KNIGHT S C: Cellular immunity in multiple sclerosis, 45
KOSTERLITZ H W, *see* HUGHES J, 157
—(editor): *Opiates and endogenous opioid peptides*, 180

L

LEEK B F: Abdominal and pelvic visceral receptors, 163
Lenman J A R: *Clinical neurophysiology*, 87
Libraries: *Directory of medical libraries in the British Isles*, 4th ed., 182
Linoleic acid inhibition test in multiple sclerosis, 6
LIVERSEDGE L A: Treatment and management of multiple sclerosis, 78
—*see* Davison A N, 86
Lymphocyte reactions of multiple sclerosis cells, 45
Lymphocytes, sensitization to myelin basic protein, 64
LYNN B: Cutaneous hyperalgesia, 103
Lysosomes, enzyme activity in multiple sclerosis, 16, 62

M

McDONALD W I & HALLIDAY A M: Diagnosis and classification of multiple sclerosis, 4
—*see* Davison A N, 86
—*see* HALLIDAY A M, 21
MACFARLANE R G: Haemostasis. Introduction to symposium, 183
McNICOL G P, *see* KERNOFF P B A, 239
MATTHEWS P B C: Muscle afferents and kinaesthesia, 137
MEADE C J, *see* MERTIN J, 67
MEADE T W & NORTH W R S: Population-based distributions of haemostatic variables, 283
Measles, relation to multiple sclerosis, 13
—-specific multiple sclerosis IgM, 38
—virus antibody findings in multiple sclerosis, 43
Mechanisms, sensory, *see* Sensory mechanisms
Mechanoreceptors, cutaneous, 99
Medical research: *Half a century of medical research. 1: Origins and policy of the Medical Research Council. 2: Programme of the Medical Research Council*, 181
Medical Research Council: Memorandum No. 45: *Aids to the examination of the peripheral nervous system*, 182
Meningitis, lymphocytic, and multiple sclerosis, 18
MERTIN J & MEADE C J: Relevance of fatty acids in multiple sclerosis, 67
Metabolism, inborn errors, role in multiple sclerosis, 68
Microneurography, human, 101
MILLAR J H D: Multiple sclerosis. Introduction to symposium, 1
Multiple sclerosis, 1–87
——aetiology, immunological aspects, 50
——age distribution, 10
——antibody, abnormal, in, 36
——antigen–antibody complexes, 37
——autoimmunity. 37, 69
——blood lipid changes in, 64
——brain in, biochemical changes, 62
——cellular immunity in, 45
——classification, 7, 8
——demyelination in, relation to virus aetiology, 34
——diagnosis, 4
———biochemical methods, 28
———immunological methods, 28
——duration, relation to virus infection, 34
——effects of exercise, 25
——epidemiology, 9
——extracerebral changes in, 64
——fatty acid metabolism in aetiology, 67
——geographical distribution, 10
——histocompatibility antigens in, 72
——immune processes, humoral factors in, 50
——immunity, cell-mediated, 37
——intermittency and virus infection, 35
——introduction to symposium, 1
——lesions in, 15
——migration, effect on life risk, 12
——*Multiple sclerosis: control of the disease*, 87
——*Multiple sclerosis research*, 86
——myelin break-down in, 63
——nomenclature, 8
——paroxysmal phenomena in, 26
——pathogenesis, relation to virus aetiology, 35
——pathology, 15
——pathophysiology, 21
——physiological tests, 4
——plaques, active, 16
———age assessment, 17
——prostaglandin changes in, 64
——psychophysical tests, 5
——racial incidence, 10
——rehabilitation, 81
——sex distribution, 10
——societies, work of, 3
——steroid therapy, 32
——synaptic transmission alterations in, 21
——temperature changes in, clinical effects, 25
——transmission, 36
——treatment and management, 78
———curative or preventive agents, 78
———dietary, 79
———palliative, 81
———restorative and reparative, 81
——virus aetiology, 34
———antibodies in, significance, 40
Muscle afferents and kinaesthesia, 137
MUSTARD J F & PACKHAM M A: Normal and abnormal haemostasis, 187
Myelin, 60
—break-down in multiple sclerosis, 63
—immunochemistry, 60
—proteolysis, 16
—remyelination, 19
—sheath, molecular architecture, 60
—structure, lipid–protein interaction, 61
Myelination, 60
Myelinolytic factors in allergic encephalomyelitis, 64

N

NATHAN P W: Pain, 149
Negroes, epidemiology of multiple sclerosis in, 11
Nerve cells: *The physiology of nerve cells*, 181
—conduction, delayed, in multiple sclerosis, 23
——effects of demyelination, 21
—demyelination, time-course of recovery, 22
Nerves, afferent, role in kinaesthesia, 137
—cutaneous, thermoreceptive fibres, 145
Nervous system, peripheral: *Aids to the examination of the peripheral nervous system*, 182
———sensory, 94
Neurochemistry: *Biochemistry and neurological disease*, 181
Neurones, sensory, spinal, 109, 110, 111
Neurophysiology: *Clinical neurophysiology*, 87
Nociceptors, 90, 101
—sensitization, 104
Nocifensor tenderness, 105
NORTH W R S, *see* MEADE T W, 283
Nucleotide mechanism, defective, in platelets, 209
Nucleus Z, 116

O

Oesophageal receptors connected with sensation, 173
Oestrogen, effect on fibrinolysis, 236
Ogston D & Bennett B (editors): *Haemostasis: biochemistry, physiology, and pathology*, 292
Opioid peptides, 157
——*Opiates and endogenous opioid peptides*, 180
Optic neuritis in multiple sclerosis, 5, 6, 23

P

PACKHAM M A, *see* MUSTARD J F, 187
Pain, 149
—control, 157
—in visceral disease, 91
—insensitivity and indifference to, 155
PAINTAL A S: Thoracic receptors connected with sensation, 169
Paraplegia, spastic, progressive, 6
Paul D H: *The physiology of nerve cells*, 181
PEAKE I R, *see* BLOOM A L, 219
Penicillins, effects on platelets, 211
Peptides: *Opiates and endogenous opioid peptides*, 180
—opioid, 157
Peroxidation of polyunsaturated fatty acids, depletion in multiple sclerosis, 68
Plasma fibrinogen, disorders of synthesis, 253
—in coagulation deficiencies, 275
Plasmin, and activation of plasminogen, 239
—interactions with fibrin, 249
——with fibrinogen, 248
Plasminogen, 239
—activators, 231, 240
—inhibitors, 240
Plasminogen–plasmin system, 239
Platelets, *see* Blood platelets.
Porterfield J S, *see* Davison A N, 86
POWELL T P S: The somatic sensory cortex, 129
Pregnancy, disseminated intravascular coagulation in, 266
Primate, temperature sense, 143
Progesterone, effect on fibrinolysis, 236
Prostaglandins as inflammatory mediators, 105
—changes in multiple sclerosis, 64
Protein, encephalitogenic, 61
Pulmonary receptors connected with sensation, 169

R

Receptors, epithelial, 163
—mucosal, 163
—*Receptors and recognition*. Series A: Vol. 1, 180
—*Somatosensory and visceral receptor mechanisms*, 180
—thoracic, connected with sensation, 169
—visceral, abdominal and pelvic, 163
Remyelination in multiple sclerosis, 19
Respiratory sensations in man, 175
RIZZA C R: Clinical management of haemophilia, 225
Russell W R: *Multiple sclerosis: control of the disease*, 87

S

Sclerosis, multiple, *see* Multiple sclerosis.
Sensation, abdominal and pelvic visceral receptors, 163
—Head's influence on development of ideas on, 91
—respiratory, in man, 175
—somaesthetic pathways, 113
—somatic, subcortical mechanisms in, 121
—thoracic receptors, 169
Sense organs, cutaneous, 97
——morphology, 97
——subcutaneous, 97
Sensory cortex, somatic, 129
—mechanisms, 89–182
——somatic, 89
——visceral, 89, 163
SHARP A A: Diagnosis and management of disseminated intravascular coagulation, 265
Skin, hyperalgesia, 103
—nerve supply, afferent, 99
—temperature changes, behavioural and physiological adjustments to, 143
Somaesthetic pathways, 113, 114
——descending systems, 119
Somatic sensation, subcortical mechanisms in, 121
—sensory cortex, 129
Somatosensory and visceral receptor mechanisms, 180
Somatosensory pathways, 113
Spinal cord, cutaneous axons and sensory neurones, 109
——grey matter, sensory function, 113
Spinocervical tract, somaesthetic function, 115
Spinoreticular somaesthetic pathway, 115
Spinothalamic tract, sensory function, 113
Steroid therapy in disseminated intravascular coagulation, 270
——in multiple sclerosis, 32
Steroids, anabolic, effect on fibrinolysis, 236
STIRLING Y, *see* MEADE T W, 283
Subcortical mechanisms in somatic sensation, 121

T

TAYLOR D G, *see* CRAWFORD N, 199
Temperature changes in multiple sclerosis, clinical effects, 25
—intensity discrimination, peripheral neural determinants, 146
—sense in primates, 143
Testosterone, effect on fibrinolysis, 236
Thalamus, sensory system, 94
—somaesthetic region, 117
Thermal sensibility, 143
Thermoreceptive fibres in cutaneous nerve, 145
Thermoreceptors, 100, 144
Thomas D P, *see* Kakkar V V, 292
THOMPSON E J: Laboratory diagnosis of multiple sclerosis: immunological and biochemical aspects, 28
Thomson A L: *Half a century of medical research*. Vol. 1: *Origins and policy of the Medical Research Council (UK)*; Vol. 2: *The programme of the Medical Research Council (UK)*, 181
Thoracic receptors connected with sensation, 169
Thrombasthenia, 190
Thrombocytopenia, 190
Thrombolysis, mechanisms, 241
Thrombolytic therapy, 241
Thrombosis: *Human blood coagulation, haemostasis and thrombosis*, 2nd ed., 292
Thyroxine, effect on fibrinolysis, 237
Trigeminal system, somaesthetic pathways, 118

U

Uraemia, platelet function in, 210
URBANIAK S J & CASH J D: Blood replacement therapy, 273
Urine, fibrin(ogen) degradation products in, 269

V

Virus antibodies in multiple sclerosis, significance, 40
—infections, demyelination in, immunopathology, 54
Visceral disease, pain of, 91
—receptors, abdominal and pelvic, 163
Visually evoked potentials in multiple sclerosis, 5
Vitamin K, role in blood coagulation, 217
von Willebrand's disease, 189, 208, 219, 231, 263
————factor-VIII variants in, 222, 231

W

WEBSTER K E: Somaesthetic pathways, 113
WIŚNIEWSKI H M: Immunopathology of demyelination in autoimmune diseases and virus infections, 54
World Health Organization: *Immunological adjuvants: Report of a WHO Scientific Group*, 87

Printed in Great Britain at The Spottiswoode Ballantyne Press by William Clowes & Sons Limited, London, Colchester and Beccles